Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Clinical Practice Guidelines – Waldenstrom’s Macroglobulinaemia

Published in 2018 - Ann Oncol (2018) 29 (Suppl 4): iv41–iv50
Authors: E. Kastritis, V. Leblond, M.A. Dimopoulos, E. Kimby, P. Staber, M.J. Kersten, A. Tedeschi & C. Buske, on behalf of the ESMO Guidelines Committee

The 2018 ESMO Clinical Practice Guidelines on Waldenström’s Macroglobulinemia (WM) are based on results from recent studies and updated analyses. New recommendations are given regarding the role of MYD88 L265P detection in the diagnosis of WM and the role of ibrutinib in the treatment of symptomatic WM. Updated recommendations on patient-specific and symptom-based treatment selection are given.

These Clinical Practice Guidelines are endorsed by the European Hematology Association (EHA)

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.